Rakovina Therapeutics Inc.
RKV.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.78% | 83.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.89% | 47.57% | |||
| Operating Income | -38.89% | -47.57% | |||
| Income Before Tax | -38.80% | -43.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.80% | -43.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.80% | -43.28% | |||
| EBIT | -38.89% | -47.57% | |||
| EBITDA | -41.16% | -53.16% | |||
| EPS Basic | -22.80% | -1.98% | |||
| Normalized Basic EPS | -22.85% | -3.22% | |||
| EPS Diluted | 4.95% | -6.98% | |||
| Normalized Diluted EPS | -22.85% | -3.22% | |||
| Average Basic Shares Outstanding | 13.02% | 40.47% | |||
| Average Diluted Shares Outstanding | 13.02% | 40.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||